{"organizations": [], "uuid": "aab56a2a9cecbf242c0ef8e0a38a228b8863cfe2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aimmune-therapeutics-announces-pro/brief-aimmune-therapeutics-announces-proposed-public-offering-of-common-stock-idUSASB0C6JB", "country": "US", "domain_rank": 408, "title": "BRIEF-Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.017, "site_type": "news", "published": "2018-02-21T05:20:00.000+02:00", "replies_count": 0, "uuid": "aab56a2a9cecbf242c0ef8e0a38a228b8863cfe2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aimmune-therapeutics-announces-pro/brief-aimmune-therapeutics-announces-proposed-public-offering-of-common-stock-idUSASB0C6JB", "ord_in_thread": 0, "title": "BRIEF-Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aimmune therapeutics inc", "sentiment": "negative"}, {"name": "brief-aimmune therapeutics announces proposed public offering of common stock feb", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Aimmune Therapeutics Inc:\n* AIMMUNE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK\n* AIMMUNE THERAPEUTICS - COMMENCED OFFERING OF UP TO $150 MILLION SHARES\n* AIMMUNE - EXPECTS TO USE PROCEEDS FROM OFFERING TO FUND ONGOING CLINICAL DEVELOPMENT OF AR101 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-21T05:20:00.000+02:00", "crawled": "2018-02-21T21:09:29.001+02:00", "highlightTitle": ""}